FMLP- and TNF-stimulated monoclonal Lym-1 antibody-dependent lysis of B lymphoblastoid tumour targets by neutrophils by Ottonello, L et al.
The ability of normal neutrophils to exert antibody-dependent
cellular cytotoxicity (ADCC) towards certain human tumour cells
is well-documented (Gale and Zighelboim, 1974; Clark and
Klebanoff, 1977; Levy et al, 1979). In particular, using heterolo-
gous polyclonal anti-target antibodies, neutrophils have been
indeed shown to lyse human B lymphoma cell lines efficiently
(Dallegri et at, 1984). More recently, neutrophils incubated with
selected murine anti-target monoclonal antibodies (mAb) were
found to mediate consistent lysis of human melanoma or neuro-
blastoma cell lines (Kushner and Cheung, 1989, 1991; Baldwin
et al, 1993; Ranhammar et al, 1994) and minimal or no lysis of
human lymphoma or leukaemia cells (Gavioli et al, 1990; Vaickus
et al, 1990). Nevertheless, using a particular (Lym-1) mAb
towards lymphoblastoid Raji cells employed as a model of B-
lymphoma cells, certain cytokines and chemotaxins have been
found to augment or promote neutrophil-mediated ADCC
(Vaickus et al, 1990; Ottonello et al, 1996). In this regard, various
cytokines have been also shown to be capable to activate anti-
neoplastic and leucocyte-mediated reactions in various mouse
models (Pickaver et al, 1972; Fady et al, 1990; Midorikama et al,
1990). In these in vivo systems, the local addition of exogenous
cytokines or their release by engineered tumour cells was indeed
found to result in immune responses, leading to tumour cell lysis
by distinct effectors including neutrophils (Colombo et al, 1992a,
1992b).
In front of the aforementioned evidence for the ability of
neutrophils to exert tumoricidal activity, the mechanisms under-
lying this function are only partially elucidated. This is particularly
true as far as the mAb-dependent neutrophil-mediated ADCC is
concerned. In the presence of the mAb 3F8 specific for the
ganglioside GD2 antigen, neutrophils were found to lyse
melanoma and neuroblastoma cell lines through a process
requiring Fcgreceptor (FcgR) type II and FcgRIII as well as adhe-
sion molecules such as CD11a-CD18 and CD11b-CD18 integrins
(Kushner and Cheung, 1992). On the other hand, using glio-
blastoma target cells sensitized by mAb 425, FcgRII was shown to
be crucial for lysis mediated by normal neutrophils (Valerius et al,
1993). The present study was planned to further investigate the
receptor requirement in mAb-dependent ADCC model systems,
such as the chemotaxin- or cytokine-stimulated Lym-1 mAb-
dependent ADCC of Raji target cells by neutrophils. We used
formyl–methionyl–leucyl–phenylalanine (FMLP) and tumour
necrosis factor alpha (TNF-a) as neutrophil stimuli, whereas
Lym-1 mAbs were employed to direct effector cells toward
B-lymphoblastoid Raji targets.
MATERIALS AND METHODS
Culture medium and reagents
The following culture medium was used: RPMI-1640 (Irvine
Scientific, Santa Ana, CA, USA) supplemented with 10% heat-
inactivated (56°C, 45min) fetal calf serum (FCS; HyClone Eur.
Ltd, Cramlington, NE, USA) and 2mmol L–1 glutamine (Irvine
Scientific) (RPMI–FCS). Hanks’ balanced salt solution (HBSS)
was from Irvine Scientific. Ficoll Hypaque was purchased from
Seromed (Berlin, Germany). Sodium chromate Cr51 was from the
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1-(5-isoquinolinnylsulphonyl)-2-methylpiperazine and wortmannin). On the contrary, an inhibitor of protein kinase C (bis-indolyl-maleimide,
BIM) was effective only in the FMLP/Lym-1 cytolytic system. Therefore, it appears that signals delivered by FMLP or TNF-a, BIM-sensitive
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(BIM) was from Calbiochem (La Jolla, CA, USA). Triton X-100,
ethidium bromide, N-formyl-met-leu-phe (FMLP), genistein
(GST), wortmannin (WMN), staurosporine (STP), 1-(5-
Isoquinolinylsulphonyl)-2-methylpiperazine (H7) and bovine
serum albumin (BSA) were purchased from Sigma Chemical Co.
(St Louis, MO, USA). Heparin was obtained from Roche (Milan,
Italy). Polyclonal human IgG were from Sclavo (Siena, Italy).
Human recombinant TNF-a was purchased from BioSource
International (Camarillo, CA, USA).
Monoclonal antibodies
The previously described (Epstein et al, 1987) mAb Lym-1
(IgG2a) was used as anti-target mAb for the cytolytic assay.
Moreover, the following mAbs were used: anti-CD32 IV.3 (IgG2a,
Fab fragments, Medarex, Annandale, NJ, USA), anti-CD16 3G8
(IgG1, native mAb and F(ab´)2 fragments, Medarex), anti-CD64
197 (IgG2a, Medarex), anti-CD18 MHM23 (Ig1, Dako AS,
Glostrup, Denmark), anti-CD18 MEM48 (IgG1, kindly provided
by V Horejsi, Praha), anti-CD18 60.3 (IgG2a, kindly provided by J
Harlan, Washington), anti-CD11a MEM25 (IgG1, kindly provided
by V Horejsi, Praha), anti-CD11b 2LPM19c (IgG1, Dako AS),
anti-CD11b 44 (IgG1, Biosource, Camarillo, CA, USA), anti-
CD11b CBRM 1/5 (IgG1, kindly provided by TA Springer,
Boston), anti-CD11c 3.9 (IgG1, Biosource), anti-CD11c KB90
(IgG1, Dako AS), anti-ICAM1 84H10 (IgG1, Immunotech,
Marseille, France), anti-CD16 FITC-conjugated mAb 3G8 (IgG1,
Pharmingen, San Diego, CA), anti-CD32 fluorescein isothio-
cyanate (FITC)-conjugated mAb FLI8.26 (IgG2b, Pharmingen),
anti-CD64 FITC-conjugated mAb 10.1 (IgG1, Pharmingen),
appropriate mouse IgG FITC-conjugated isotype controls 107.3
and 49.2 (Pharmingen).
Neutrophil preparation
Heparinized venous blood (heparin 10 U ml–1) was obtained from
healthy volunteers (20–45 years old) after informed consent. No
donor had an infectious disease or was under medication either at
the time of sampling or for 2 weeks before sampling. Neutrophils
were prepared by dextran sedimentation, followed by centrifuga-
tion (400 g, 30 min) on Ficoll-Hypaque density gradient, as
previously described (Ottonello et al, 1996). Contaminating
erythrocytes were removed by hypotonic lysis (Ottonello et al,
1996). PMNs resuspended in RPMI–FCS were > 97% pure viable,
as determined by the assays described above.
Target cells
Lymphoblastoid Raji cells (Ottonello et al, 1996) were used as
targets in the cytolytic assays. The Raji cell line was grown in
RPMI–FCS and subcultured every 3 days. The capacity of these
cells to bind Lym-1 antibody was measured by indirect immuno-
fluorescence with flow cytometry using a rabbit anti-mouse IgG
F(ab´)2 polyclonal antibody conjugated with FITC (Dako)
(Ottonello et al, 1996). For cytolytic assays, 4 ´ 106 Raji cells were
labelled with 100–200 mCi sodium chromate Cr51 by incubating
for 1 h at 37°C (final volume 0.5 ml, medium: RPMI-1640 plus
5% FCS). After washing, labelled cells were resuspended in
RPMI–FCS.
Cytolytic assays
Cytolytic activity of neutrophils was measured as described else-
where in detail (Dallegri et al, 1984; Ottonello et al, 1996). Briefly,
target cells (2 ´ 104) were mixed with neutrophils at an
effector:target ratio of 20:1, with and without 10 mg ml–1 Lym-1
mAb (Epstein et al, 1987) and/or 1 mM FMLP or 1 ng ml–1 TNF-a
appropriately diluted in RPMI–FCS. The effector:target ratio of
20:1 was chosen on the basis of preliminary experiments, also
taking into account previous observations (Ottonello et al, 1996).
In fact, the per cent cytolysis at effector:target ratios of 20:1 and
40:1 was 28.33 ± 6.43 and 32.5 ± 3.08 (mean ± 1 standard devia-
tion (s.d.), n = 3, P > 0.05) in the TNF-a system, whereas it was
23.97 ± 10.82 and 26.87 ± 7.34 (mean ± 1 s.d. n = 3, P > 0.05) in
the FMLP system. Experiments were carried out in the absence or
presence of the various mAbs and reagents used to probe the
cytolytic process. The assays were carried out in triplicate and in a
final volume of 150 ml, using round-bottom microplates (Falcon,
Becton-Dickinson Italia, Milano, Italy). After 14-h incubation in
humidified atmosphere of 95% air and carbon dioxide, the Cr51-
release was determined in the formula 100 ´ (E-S)/(T-S), where E
is the cpm released in the presence of effector cells, T is the cpm
released after target cells with 5% Triton X-100, and S is the cpm
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Figure 1 Neutrophil-mediated cytolysis in the absence or presence of
10 mg ml–1 Lym-1 and/or 1 mM FMLP or 1 ng ml–1 TNF-a. Cr51-labelled Raji
target cells were at 2 ´ 104. The neutrophil:Raji cell ratio was 20:1. The
incubation time was 14 h. (A) The lysis in the presence of both Lym-1 and
FMLP was significantly higher than that in the presence of FMLP or that in
the presence of Lym-1 alone, P < 0.001. (B) The lysis in the presence of both
Lym-1 and TNF-a was significantly higher than that in the presence of TNF-a
or that in the presence of Lym-1 alone, P < 0.001spontaneously released by target cells incubated with medium
alone (< 18%).
Immunofluorescence analysis
Neutrophils (106 cells) were incubated for 30 min at 4°C in the
presence of FITC-labelled mAbs towards FcgRI, FcgRII, FcgRIII
or control mAbs. Polyclonal human IgG (4 mg ml–1) was added
during incubation to inhibit possible non-specific binding of mAbs
to high affinity FcgR for IgG. After incubation, the cells were
washed in phosphate-buffered saline (PBS) plus 1% BSA and
resuspended in PBS for analysis on a Coulter flow cytometer. To
compare results, relative fluorescence intensities (RFI) were calcu-
lated as the ratios between the linear fluorescence intensity (FI)
obtained with the relevant mAb and the FI obtained with the
control mAb.
Statistical analysis
Results were expressed as mean ± 1 s.d. and/or a median with the
95% confidence interval (CI). Statistical differences were analysed
by the Mann–Whitney test. Significance was accepted when
P < 0.05.
RESULTS
Intervention of neutrophil FcgR and b2-integrins in Lym-
1 mAb-dependent FMLP- and TNF-a stimulated lysis
When incubated with Cr51-labelled Raji target cells, human
neutrophils failed to cause lysis (per cent Cr51 release: 0.25 ± 0.77,
mean ± 1 s.d., n = 21 with a median of 0.00 and a 95% CI from
–0.10 to 0.60). As shown in Figure 1, neither FMLP nor TNF-a
activated neutrophil lytic activity whereas the anti-target mAb
Lym-1 caused low but significant levels of lysis. The simultaneous
addition of Lym-1 and FMLP, or Lym-1 and TNF, to the neutrophil-
target cell co-cultures resulted in consistent amplification of the
lysis (Figure 1). In the presence of both FMLP and Lym-1, the lysis
was 20.79 ± 10.87 (mean ± 1 s.d., n = 77) with a median of 20.60
(95% CI, 18.32–23.26). Moreover, in the presence of both TNF-a
and Lym-1, the lysis was 26.83 ± 18.36 (mean ± 1 s.d., n = 39) with
a median of 21.80 (95% CI, 20.87–32.78). These data suggest that
FMLP and TNF-a synergistically cooperate with the anti-target
mAb Lym-1 to stimulate neutrophil cytolytic activity. As shown in
Figure 2, the anti-FcgRII mAb IV.3 Fab fragments (anti-CD32)
inhibited the lysis of target cells by neutrophils incubated with
Lym-1 and FMLP. On the other hand, Lym-1/FMLP-dependent
mAb-mediated ADCC by neutrophils 333
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Figure 2 Effect of the anti-CD32 (FcgRII) mAb IV.3 Fab fragments and anti-CD16 (FcgRIII) mAb 3G8 F(ab´)2 fragments on FMLP- and TNF-a-stimulated
neutrophil-mediated Lym-1 antibody-dependent cytolysis. Cr51-labelled Raji cells were at 2 ´ 104. The neutrophil: Raji cell ratio was 20:1. The incubation time
was 14 h. FMLP-stimulated lysis: (A) cytolysis in the absence versus that in the presence of 4 mg ml–1 IV.3: P = 0.0286. (B) Cytolysis in the absence versus that
in the presence of 4 mg ml–1 3G8: P = 0.685. TNF-a-stimulated lysis: (C) cytolysis in the absence versus that in the presence of 4 mg ml–1 IV.3: P = 0.0286.
(D) Cytolysis in the absence versus that in the presence of 4 mg ml–1 3G8: P = 1.000cytolysis was unaffected by the anti-FcgRIII mAb 3G8 F(ab´)2 frag-
ments (Figure 2). Similar results were obtained by using these anti-
FcgR mAbs to investigate Lym-1/TNF-a-dependent lysis (Figure
2). Moreover, it is of note that native 3G8 mAb inhibited both TNF-
a (26.24 ± 10.30 vs 3.1 ± 4.1, mean ± 1 s.d., n = 7, P = 0.0006) and
FMLP system (20.32 ± 9.33 vs 3.74 ± 2.92, mean ± 1 s.d., n = 5,
P = 0.0079). Finally, a panel of mAbs against various members of
b2-integrins were tested (data not shown), but only the anti-CD18
mAb MEM 48 inhibited the Lym-1/FMLP- and Lym-1/TNF-a-
stimulated neutrophil-mediated lysis (Figure 3). Therefore, FcgRII
and b2-integrins are strictly and equally required in both the FMLP-
and TNF-a-dependent cytolytic model systems. Finally, mAb 197
specific for FcgRI (CD64) did not affect neutrophil-mediated lysis
(FMLP system: 27.47 ± 7.03 and 29.60 ± 7.60 in the absence and
presence of 4 mg ml–1 mAb 197; TNF-a system: 26.07 ± 5.02 and
33.0 ± 4.39 in the absence and presence of 4 mg ml–1 mAb 197,
mean ± 1 s.d., n = 3).
Effect of inhibitors of distinct signalling pathways on
neutrophil ADCC activity stimulated by FMLP and TNF-a
In order to understand if different post-receptor signal transduction
pathways underlie neutrophil cytolytic activity in the two model
systems, i.e. the Lym-1/TNF-a vs the Lym-1/FMLP system, the
effect of various inhibitors was studied. GST, an inhibitor of tyro-
sine kinase (Rollet et al, 1994), staurosporin (STP) and H-7, which
have been shown to affect the activity of various protein kinases
(Ginis and Tauber, 1990) and WMN, which inhibits both phos-
phatidylinositol-3-kinase and phospholipase D (Vlahos et al,
1995), were found to equally suppress neutrophil activity in
Lym-1/TNF-a and Lym-1/FMLP system (Figure 4). Moreover,
pertussis toxin (PT, 2 mg ml–1) was found to equally inhibit
TNF-a- and FMLP-exposed neutrophils (% Cr51 release, TNF-a
system: 16.00 ± 9.47 and 2.78 ± 4.54 in the absence and presence
of PT respectively, mean ± 1 s.d., n = 6, P = 0.0152; FMLP
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Figure 3 Effect of the anti-CD18 mAb MEM48 on the FMLP- and TNF-a-
stimulated neutrophil-mediated Lym-1 antibody-dependent cytolysis. Cr51-
labelled Raji cells were at 2 ´ 104. The neutrophil:Raji cell ratio was 20:1. The
incubation time was 14 h. (A) FMLP-stimulated lysis: cytolysis in the absence
versus that in the presence of MEM48: P = 0.004. (B) Cytolysis in the
absence versus that in the presence of MEM48: P = 0.004
Figure 4 Effect of genistein (GST), staurosporin (STP), 1-(5-
Isoquinolilylsulphonyl)-2-methylpiperazine (H7) and wortmannin (WMN) on
the FMLP- and TNF-a-stimulated Lym-1 antibody-dependent lysis. Cr51-
labelled Raji cells were at 2 ´ 104. The neutrophil:Raji cell ratio was 20:1.
Incubation time was 14 h. Black bars show the results with FMLP and the
white bars those with TNF-a. Results are expressed as mean ± 1 s.d. of the
inhibitory dose 50% (IC50). The numbers of experiments were five for GST
and STP and three for H7 and WMN. For each substance, cytolysis in the
presence of FMLP versus that in the presence of TNF-a: P > 0.05
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)system: 10.73 ± 7.1 and 0.01 ± 0.04 in the absence and presence of
PT respectively, mean ± 1 s.d., n = 6, P = 0.0022). On the contrary,
BIM, an inhibitor of protein kinase C (Toullec et al, 1991),
suppressed the lysis induced by Lym-1/FMLP-activated
neutrophils without affecting the lysis induced in parallel experi-
ments by Lym-1/TNF-a (Figure 5). The cytolytic activity of Lym-
1/TNF-a-stimulated neutrophils was also unaffected by a dose of
BIM ten times higher than that used in experiments reported in
Figure 5 (data not shown).
Analysis of FcgR expression on neutrophils exposed to
FMLP and TNF-a
The exposure of neutrophils to 1 mM FMLP or 1 ng ml–1 TNF-a
did not significantly affect (P > 0.05) the levels of FcgRII expres-
sion (relative fluorescence intensities, i.e. RFI were 5.01 ± 1.36,
4.1 ± 0.8, 4.1 ± 0.3 after cell incubation for 14 h in the absence or
presence of FMLP and TNF-a respectively, mean ± 1 s.d., n = 3).
Moreover, neutrophil exposure (14 h) to FMLP or TNF-a caused a
decrease in FcgRIII expression (RFI were 5.6 ±3.9, 2.2 ±0.5 and 2.2
± 0.4 after cell incubation for 14 h in the absence or presence of
FMLP and TNF-a respectively, mean ± 1 s.d., n = 3). Finally,
neutrophils from healthy donors did not express FcgRI (RFI:
0.9  ± 0.1, mean ± 1 s.d., n = 3). Nevertheless, very low levels of
FcgRI could be detected on the surface of these cells after incubation
(14 h) in medium (RFI: 1.5 ± 0.2, mean ± 1 s.d., n = 3). Comparable
levels of FcgRI expression were detected after neutrophil incubation
(14 h) with FMLP or TNF-a (RFI: 1.5 ± 0.2 and 1.6 ± 0.2 for cells
exposed to FMLP and TNF-a respectively, mean ± 1 s.d., n = 3).
DISCUSSION
A preliminary clinical trial with Lym-1 intravenous infusion,
carried out in some patients with refractory lymphoma, showed an
evident reduction of lymph node size only in some cases (Hu et al,
1989). Although a number of factors can contribute to these partial
responses, the inadequacy of host immune effector systems is
likely to play a relevant role. In order to improve Lym-1 antibody-
based therapeutic approaches, it is therefore critical to understand
whether cell-mediated cytolysis can be enhanced by biological
response modifiers.
The present study shows that mAb Lym-1, per se ineffective or
endowed with a very low activity, interacts synergistically with
FMLP or TNF to trigger neutrophil ADCC towards B lymphoblas-
toid tumour targets. These findings confirm and extend our initial
observations (Ottonello et al, 1996). Moreover, the present data
suggest that the two systems, i.e. FMLP- and TNF-a-dependent
Lym-1 ADCC, share a variety of characteristics including certain
receptor and post-receptor requirements. These findings may be a
starting point to develop anti-tumour immune reactants, such as
anti-tumour mAbs conjugated with TNF-a or FMLP to be consid-
ered for in vivo administration (Obrist et al, 1991).
The two cytolytic systems appear to be strictly dependent on the
intervention of FcgRII without the involvement of FcgRIII. This
directly proves the actual role of FcgRII as cytolytic trigger in
neutrophil mAb-dependent ADCC. In fact, this type of receptor
was identified as major trigger molecule for neutrophil ADCC by
using hybridoma target cells expressing antibodies to various
neutrophil surface antigens (Graziano and Fanger, 1987; Elsässer
et al, 1996). In this system, neutrophils were indeed able to lyse
hybridoma cells expressing antibodies to FcgRII but not those
bearing mAb specific for FcgRIII (Graziano and Fanger, 1987;
Elsässer et al, 1996). Consistent with our findings, FcgRII but not
FcgRIII were found to cluster at the effector-target interface during
neutrophil ADCC towards sheep erythrocytes (Petty et al, 1989).
Moreover, Valerius and co-workers provided evidence for a crucial
role for FcgRII in the lysis of mAb sensitized glioblastoma cells by
normal neutrophils (Valerius et al, 1993), whereas Repp and co-
workers described the intervention of this type of receptor in
neutrophil-mediated lysis of Daudi lymphoma cells opsonized
with specific rabbit anti-serum (Repp et al, 1991). On the other
hand, the participation of additional cell surface molecules is
required for optimal activity, as suggested by the ability shown
herein of an anti-CD18 mAb to suppress Lym-1 ADCC. This
indicates the intervention of b2 integrins, generally thought to
strengthen adhesion between effector and target cells. The finding
is consistent with previous evidences for b2 integrins intervention
in neutrophil ADCC systems carried out with polyclonal anti-
target antibodies (Anderson et al, 1984; Kohl et al, 1984). Finally,
our data are in agreement with those of other authors (Kushner and
Cheung, 1992) showing the requirement for CD18 integrins in
neutrophil-mediated mAb-dependent lysis of tumour cells.
mAb-mediated ADCC by neutrophils 335
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Figure 5 Effect of bis-indolyl-maleimide (BIM, 5 mM) on the FMLP- (A) and
TNF-a-stimulated (B) neutrophil-mediated Lym-1 antibody-dependent
cytolysis. Cr51-labelled Raji cells were at 2 ´ 104. The neutrophil:Raji cell ratio
was 20:1. The incubation time was 14 h. (A) Cytolysis in the absence versus
that in the presence of BIM: P = 0.0087. (B) Cytolysis in the absence versus
that in the presence of BIM: P = 0.008Using melanoma and neuroblastoma cell lines as targets,
Kushner and Cheung have shown that mAb-ADCC by neutrophils
requires both FcgRII and FcgRIII (Kushner and Cheung, 1989,
1992). Also, other authors have proposed a role for FcgRIII in
neutrophil mAb-mediated tumour lysis (Gavioli et al, 1991). No
final explanation for the discrepancies about the role of FcgRIII in
ADCC between these findings and our present conclusions is
available. Nevertheless, it is of note that, in front of the incapacity
of anti-FcgRIII F(ab´)2 fragments to inhibit neutrophil Lym-1
ADCC, the same but entire anti-FcgRIII mAb (3G8) inhibited the
lysis efficiently. This is consistent with the recently shown ability
of 3G8 mAb to block the ligand-binding site of FcgRII with its Fc
portion (Flesch et al, 1997). Therefore, the inhibition of ADCC by
3G8 mAb observed by Kushner and Cheung (1989, 1992) might
reflect the blockade of FcgRII. Similarly, neutrophil-mediated
FcgRII-dependent phagocytosis was found to be susceptible to
inhibition by native mAb 3G8 (Flesch et al, 1997). On the other
hand, it is known that chemoattractant-stimulated neutrophils
undergo shedding of FcgRIII (Huizinga et al, 1990; Tosi and
Zakem, 1992), a phenomenon balanced at least in part by a
concomitant translocation of receptors from intracellular storage
compartments (Tosi and Zachem, 1992). In substantial agreement
with these studies, the prolonged exposure to FMLP or TNF-a
resulted in a partial down-regulation of the FcgRIII expression.
Nevertheless, owing to the considerable levels of FcgRIII expres-
sion even after 14 h incubation with FMLP and TNF-a, i.e. ~ 40%
of the values detectable on cells incubated in medium alone, it
seems unlikely that a stimulus-induced loss of FcgRIII can account
for the herein found inability of this receptor to play a role in
Lym-1 ADCC.
It has been shown that FcgRI, inducible in neutrophils by inter-
feron gamma (IFN-g) and granulocyte colony-stimulating factor
(G-CSF) (Buckle and Hogg, 1989; Repp et al, 1991; Elsässer et al,
1996; Valerius et al, 1997) is effective in activating neutrophil lytic
potential, as demonstrated in reverse cytotoxic assays against anti-
FcgRI mAb-producing hybridoma targets (Elsässer et al, 1996)
and in tumour cell lysis mediated by bi-specific mAbs with one
specificity for FcgRI (Elsässer et al, 1996; Valerius et al, 1997;
Würflein et al, 1998). In agreement with other authors (Buckle and
Hogg, 1989), neutrophils from healthy donors did not express
FcgRI. This receptor was, however, detected after 14-h incubation,
although the amount was very low, confirming previous findings
(Buckle and Hogg, 1989). Nevertheless, neither FMLP nor TNF-a
were found to affect neutrophil FcgRI expression and, on the other
hand, neither FMLP- nor TNF-a-stimulated Lym-1 ADCC were
inhibited by the anti-FcgRI mAb 197. Therefore, this Fc receptor
has no role under our conditions. This consistent with the known
inability of normal neutrophils to lyse anti-FcgRI mAb-expressing
hybridoma cells (Elsässer et al, 1996).
Since FMLP and TNF-a were herein found to be devoid of
effects on FcgRII expression but capable of triggering FcgRII-
mediated ADCC, the present data are consistent with the possi-
bility that both FMLP and TNF-a act on post-Fc receptor signal
transduction systems. It is well-known that post-receptor intracel-
lular signalling pathways leading to specific neutrophil functional
responses involve various kinases, phospholipases, calcium and
certain signal-transducing proteins such as, for instance, G-
proteins (Nishizuka, 1995). The inhibitory activity of pertussis
toxin in the FMLP–ADCC system can conceivably involve inhibi-
tion of toxin-sensitive and FMLP receptor-coupled G-proteins
(Snyderman and Uhing, 1992). As neither TNF-a-dependent cell
stimulation nor b2-integrin signalling are known to involve
pertussis toxin-sensitive pathways (Dinarello, 1992; Hynes, 1992),
the inhibitory activity of the toxin in the TNF-a-dependent ADCC
system might be attributed to the blockade of the pertussin toxin-
sensitive src-like tyrosine kinase fgr pathway which has been
previously shown to be associated with the FcgRII signal transduc-
tion (Hamada et al, 1993; Zhou et al, 1995). This FcgR has been
indeed shown to initiate transmembrane signals that can involve
pertussis toxin-sensitive pathways (Gresham et al, 1987; Feister et
al, 1988). On the other hand, the protein kinase C inhibitor BIM
was found to suppress FMLP- but not TNF-a-dependent ADCC,
suggesting that it selectively interferes with FMLP signal trans-
duction. On the contrary, other chemicals, including inhibitors of
tyrosine kinase and phosphatidylinositol-3-kinase were equally
effective in the FMLP- and TNF-a-system, suggesting that the two
ADCC conditions share common activating circuits.
In conclusion, taking into account the present observations,
Lym-1 ADCC can be envisaged as a process involving the coordi-
nated intervention of various neutrophil receptors. In other terms,
signals delivered by FMLP or TNF, BIM-sensitive and insensitive
respectively, converge and synergize with those from G-protein
coupled FcgRII and presumably b2-integrins to induce the activa-
tion and expression of the neutrophil cytolytic potential.
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